FindTrial
Sign In

ASLAN001

DRUG5 trials

Sponsors

ASLAN Pharmaceuticals, National University Hospital, Singapore, National Cancer Centre, Singapore

Conditions

Advanced/ Metastatic Hepatocellular CarcinomaCancer of StomachCancer of the StomachGastric CancerGastric NeoplasmsHER2-positive Breast CancerMetastatic Breast CancerSolid Tumor

Phase 1

Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine
CompletedNCT02648425
ASLAN PharmaceuticalsSolid Tumor
Start: 2014-08-05End: 2017-09-15Updated: 2018-10-25
Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC)
NCT03499626
National University Hospital, SingaporeAdvanced/ Metastatic Hepatocellular Carcinoma
Start: 2017-05-05End: 2021-05-05Target: 22Updated: 2018-04-17

Phase 2

A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2
CompletedNCT01614522
ASLAN PharmaceuticalsCancer of Stomach, Cancer of the Stomach, Gastric Cancer +2
Start: 2012-03-31End: 2013-03-31Updated: 2015-01-14
Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab
CompletedNCT02338245
ASLAN PharmaceuticalsMetastatic Breast Cancer
Start: 2014-12-29End: 2016-08-25Target: 200Updated: 2017-10-17
Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer
TerminatedNCT07166367
National Cancer Centre, SingaporeHER2-positive Breast Cancer
Start: 2016-08-11End: 2020-01-14Updated: 2025-09-10

Related Papers

Differences in sensitivity to new therapies between primary and metastatic breast cancer: A need to stratify the tumor response?
Cancer Medicine2022-09-134 citations
Targeted therapies: How can CT imaging improve evaluations and help understand mechanism of drug action?
Journal of Clinical Oncology2020-05-20
Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies.
Journal of Clinical Oncology2019-01-2914 citations
Initial signals of efficacy in cholangiocarcinoma from a phase Ib trial of varlitinib in combination with doublet chemotherapy (cisplatin + 5-fluororacil or capecitabine).
Journal of Clinical Oncology2017-05-20